Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating COPD Patients Initiating Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy Within a Large US Health Insurer Database

Poster No. S17 (A400)

Gässler & Knapp, LLC, Cary, NC, USA; Gässler & Knapp, LLC, Durham, NC, USA

References


Results

Table 1. Post-IPTW Demographic and Clinical Comparison

<table>
<thead>
<tr>
<th>Outcome Measures</th>
<th>Post-IPTW</th>
<th>B/F</th>
<th>ASD (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean, SD)</td>
<td>70.5 (9.9)</td>
<td>70.7 (9.8)</td>
<td>1.5</td>
</tr>
<tr>
<td>Female, %</td>
<td>49.1</td>
<td>49.2</td>
<td>0.3</td>
</tr>
<tr>
<td>Commercial, %</td>
<td>15.8</td>
<td>15.8</td>
<td>0.0</td>
</tr>
<tr>
<td>Medicare Advantage, %</td>
<td>84.2</td>
<td>84.2</td>
<td>0.0</td>
</tr>
<tr>
<td>Medicare Part D Low-Income Subsidy, %</td>
<td>27.2</td>
<td>27.3</td>
<td>0.2</td>
</tr>
<tr>
<td>COPD Severity Score, mean (SD)</td>
<td>23.4 (4.7)</td>
<td>23.4 (4.6)</td>
<td>0.6</td>
</tr>
<tr>
<td>Any Rescue Medication Fill, %</td>
<td>41.2</td>
<td>41.1</td>
<td>0.1</td>
</tr>
<tr>
<td>COPD-related Outpatient Visits, %</td>
<td>47.6</td>
<td>48.1</td>
<td>0.9</td>
</tr>
<tr>
<td>COPD-related Pulmonological Visits, %</td>
<td>27.3</td>
<td>27.2</td>
<td>0.1</td>
</tr>
</tbody>
</table>

Figure 1. Adherence over the 12-Month Follow-Up Period

Table 2. Rescue Medication Use in the 12-Months Following Treatment Initiation

<table>
<thead>
<tr>
<th>Outcome Measures</th>
<th>UMEC/VI</th>
<th>B/F</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any fill for rescue medications (%)</td>
<td>51.1</td>
<td>58.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>SABA</td>
<td>46.2</td>
<td>50.6</td>
<td></td>
</tr>
<tr>
<td>SAMA</td>
<td>1.9</td>
<td>2.9</td>
<td></td>
</tr>
<tr>
<td>SABA/SAMA</td>
<td>10.7</td>
<td>14.7</td>
<td></td>
</tr>
</tbody>
</table>

Figure 2. Rescue Medication Use over 12-Month Follow-Up Period

<table>
<thead>
<tr>
<th>Outcome Measures</th>
<th>UMEC/VI (n=4082)</th>
<th>B/F (n=9529)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean PDC</td>
<td>0.47</td>
<td>0.38</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>
| Percentage of patients with 
PDC ≥0.80 | 24.6% | 14.6% | <0.001 |

Conclusions

After adjusting for confounders using IPTW, patients with COPD initiating UMEC/VI as initial maintenance therapy had significantly higher mean adherence, as well as a higher proportion of patients that were adherent (PDC>0.80), compared to patients initiating B/F.

Patients treated with UMEC/VI also filled fewer canister-equivalents of rescue medication, annually.

Reference


Acknowledgments

- CII-Affiliated Databank Database is owned/operated by OptumInsight, Eden Prairie, MN.